Artificial Blood Substitutes Market – Insights into how contours of market will change in coming years – BioSpace

The global artificial blood substitutes market is predicted to register stellar growth rate in the forthcoming years. The presence of a large patient population that requires blood transfusion during surgeries, trauma, and for other blood disorders, which remains unmet due to shortage of blood supply has necessitated creation of artificial blood substitutes.

Artificial blood substitutes are primarily used to mimic oxygen carrying capacity of biological blood and expand the blood volume in the human body. Use of artificial blood substitutes is at present considered an alternate method for blood transfusion. Further research is underway to develop more alternate methods for blood transfusion, including developing human red blood cells (RBCs) from stem cells of donors blood.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5793

The research report provides an in-depth analysis of the artificial blood substitutes market over the forecast period. The report covers each and every key aspect pertinent to the market, including market dynamics, segmentation, and competitive scenario. The assessment of artificial blood substitutes market presented herein could serve as a valuable guide for both existing market participants, and the ones seeking entry in this market.

Artificial Blood Substitutes Market: Competitive Landscape and Notable Developments

The initial clinical trials for blood substitutes are recorded as early as early 1600, wherein milk, beer, urine, sheeps blood, and perfluorochemicals were administered as blood substitutes for animal and human subjects.

In successive periods, clinical trials of milk transfusion, including goats milk in large quantities were carried out but in vain. Clinical trials also involved injecting human milk that were futile too, which led researchers concede human milk not to be a substitute for blood.

With continual extensive research, over long periods, scientists have attained some success to develop blood substitutes. Artificial blood thus far developed can substitute red blood cells. While biological human blood performs several different functions, artificial blood performs the sole purpose of transporting oxygen and carbon dioxide in the body.

Established biotechnology companies in the ambit are engaged to develop blood substitutes. Such pursuits primarily involve developing oxygen carriers similar or above the capacity of biological blood. With concerted efforts of some top-notch biotechnology companies, namely HEMARINA SA, KaloCyte Inc. and Hemoglobin Oxygen Therapeutics LLC blood substitutes are available as oxygen carrier based on hemoglobin and perfluorocarbon-based oxygen carrier.

Nevertheless, presence of several well-established biotechnology companies engaged in the development of blood substitutes portrays a competitive yet moderately consolidated vendor landscape of the artificial blood substitutes market.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=5793&ltype=S

Artificial Blood Substitutes Market: Key Trends

Worldwide, excessive blood loss due to traumatic injuries and diseases is responsible for vast number of deaths every year. Limited availability of fresh blood and small storage periods of fresh blood for such situations have necessitated development of artificial blood substitutes.

With continual experiments over long periods, scientists have thus far been able to create substitutes to mimic oxygen carrier capacity of biological blood. Development of perfluorochemical-based oxygen carrier and hemoglobin-based oxygen carrier and provide thrust to the artificial blood substitutes market.

Besides this, advent of stem cell therapy is poised to create new opportunities for demand of artificial blood substitutes.

However, on the downside, lower shelf life of artificial blood products and stringent regulatory approval process for these products restrain the growth of artificial blood substitutes market.

Artificial Blood Substitutes Market: Regional Outlook

North America is at the fore for demand within overall artificial blood substitutes market. Presence of advanced healthcare combined with awareness of individuals for alternate demonstrated therapies account for leading revenue share of the region.

Continual advances in stem cell therapy further indicates sustained growth of artificial blood substitutes market in the region.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5793

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Follow this link:
Artificial Blood Substitutes Market - Insights into how contours of market will change in coming years - BioSpace

Global Stem Cell Therapy Market 2020 Segmentation, Top Manufacturers, Demand, Growth, Trend, Opportunity and Forecast to 2025 – 3rd Watch News

The global Stem Cell Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 18.9% in the forecast period of 2020 to 2025 and will expected to reach USD 828.7 million by 2025, from USD 415.3 million in 2019. The Stem Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Get Latest Sample for Global Stem Cell Therapy Market Report @ https://www.arcognizance.com/enquiry-sample/737506

Market segmentation Stem Cell Therapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Stem Cell Therapy market has been segmented into Autologous, Allogeneic, etc.

By Application, Stem Cell Therapy has been segmented into Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others, etc.

Regions and Countries Level Analysis Regional analysis is another highly comprehensive part of the research and analysis study of the global Stem Cell Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Stem Cell Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Stem Cell Therapy market. The report offers in-depth assessment of the growth and other aspects of the Stem Cell Therapy market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Stem Cell Therapy markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Access Complete Global Stem Cell Therapy Market Report @ https://arcognizance.com/report/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Competitive Landscape and Stem Cell Therapy Market Share Analysis Stem Cell Therapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Stem Cell Therapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Stem Cell Therapy sales, revenue and market share for each player covered in this report.

The major players covered in Stem Cell Therapy are: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell, Takeda (TiGenix), etc. Among other players domestic and global, Stem Cell Therapy market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Buy The Report @ https://www.arcognizance.com/purchase/737506

Major Point of TOC:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Company Profiles

Chapter Three: Market Competition, by Players

Chapter Four: Market Size by Regions

Chapter Five: North America Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East & Africa Revenue Stem Cell Therapy by Countries

Chapter Ten: Market Size Segment by Type

Chapter Eleven: Global Stem Cell Therapy Market Segment by Application

Chapter Twelve: Global Stem Cell Therapy Market Size Forecast (2021-2025)

To Check Discount of Stem Cell Therapy Market @ https://www.arcognizance.com/discount/737506

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.

ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact US: Name: Analytical research cognizance Address: 100 Church Street, 8th floor, Manhattan, New York 10007 Phone: +1 (646) 403-4695 +91 90967 44448 Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read the original post:
Global Stem Cell Therapy Market 2020 Segmentation, Top Manufacturers, Demand, Growth, Trend, Opportunity and Forecast to 2025 - 3rd Watch News

Duchenne Muscular Dystrophy Treatment Market to Witness over XX% Growth ‘in Revenue During the COVID-19 Pandemic Scenario – Kentucky Journal 24

Duchenne Muscular Dystrophy (DMD) is a muscle degeneration and is a genetic disorder which is X-linked recessive. However, it is also inherited from parents or caused due to a new mutation. There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.

Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the duchenne muscular dystrophy treatment. Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants and also the last-stage DMD patients. In the last few years, there has been rapid development in the duchenne muscular dystrophy therapeutics. However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness.

Duchenne Muscular Dystrophy (DMD) is a type of muscular disorder due to which most of the people are unable to walk at a very early stage and the affected muscles look larger due to the fat content. The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability. Although, the treatment to control and reduce the signs and symptoms is available, yet there is no cure for DMD. Key players in the market are also trying to spread awareness about DMD along with the investment in finding a treatment for the disease. Meanwhile, human clinical trials are also underway to find out effective therapy.

Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/211

Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy. Meanwhile, there is an ongoing research on gene therapy, exon skipping drugs, and stem cell therapy to treat duchenne muscular dystrophy in a better way. Current pharmacological interventions for duchenne muscular dystrophy include approaches to mitigate downstream and secondary pathological mechanisms and solutions targeting primary defect. Patients with DMD are not able to produce a protein known as dystrophin. Hence, a variety of new medications are being developed to replace dystrophin. Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin. However, delay in diagnosis and the high cost of treatment and drugs are some of the factors restricting the growth of the market.

The global duchenne muscular dystrophy market is segmented into therapy, distribution channel, product type, and region. The product type is further segmented into corticosteroids, NSAIDs, and other products. Among these, corticosteroids are likely to witness the highest growth during the forecast period. By the end of 2026, corticosteroids are estimated to bring in more than US$ 9,000 million revenue.

Based on the distribution channel, the global duchenne muscular dystrophy market segmentation includes online pharmacies, retail pharmacies, and hospital pharmacies. Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market. Hospital pharmacies are anticipated to exceed US$ 6,000 million revenue towards the end of 2026.

On the basis of therapy, the market segmentation includes Exon Skipping Approach, Mutation Suppression, and other therapies. Mutation suppression therapy is expected to witness strong growth throughout the forecast period. By the end of 2026, mutation suppression therapy is estimated to bring in more than US$ 6,400 million revenue.

Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/211

Europe is expected to be the dominating region in the global duchenne muscular dystrophy market during the forecast period. Owing to the high rate of people suffering from duchenne muscular dystrophy, Europe is witnessing the growth in adoption of treatment for muscular dystrophy. Also, various treatments are approved or under review to treat duchenne muscular dystrophy in Europe. This is also one of the reasons for the growth of the market in Europe.

Some of the players in Duchenne Muscular Dystrophy Treatment Market are Bristol-Myers Squibb(U.S), FibroGen, Inc (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc.(U.S) , NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co (Japan), Sarepta Therapeutics (U.S), Inc., Santhera Pharmaceuticals, PTC Therapeutics (Switzerland)

Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/211

View post:
Duchenne Muscular Dystrophy Treatment Market to Witness over XX% Growth 'in Revenue During the COVID-19 Pandemic Scenario - Kentucky Journal 24

Hodgkin’s Lymphoma in 8 Major Markets, 2019-2029 – Anticipated Label Expansions of Currently Marketed Therapies is a Key Driver – GlobeNewswire

July 03, 2020 06:24 ET | Source: Research and Markets

Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Hodgkin's Lymphoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

The World Health Organization (WHO) classifies HL into two main types: classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL), which CHL accounts for 95% of cases. Historically, treatment of HL has been mostly reliant on chemotherapies, radiotherapy and SCT and has lacked a rapidly advancing pipeline.

In recent years however, the arrival of three novel agents reflect a change in the treatment paradigm, shifting from cytotoxic therapies to immunotherapies and novel cell-based therapies.

The publisher is expecting a total of 6 new entrants to launch over the forecast period in the 8MM from 2019-2029, while specific marketed agents are expected to move into earlier lines of treatment as novel combinations. The main competition will between drug entering the first-line setting and novel combinations within the salvage setting for relapsed and refractory patients. Given the high cure rate for this indication, these two early setting are the most determinant of global sales for Hodgkin's lymphoma.

Key Highlights

Report Scope

Key Questions Answered

Key Topics Covered

1 Table of Contents 1.1 List of Tables 1.2 List of Figures

2 Hodgkin's Lymphoma: Executive Summary 2.1 Moderate Market Growth Expected for Hodgkin's Lymphoma During 2019-2029 2.2 Drug Developers Focusing On Combination Therapies Featuring Marketed Products with Novel Therapies 2.3 Need for More Effective Therapies to Reduce the Use of Chemotherapy and Delay Stem Cell Transplant is Partially Attainable 2.4 Growth in the 8MM Is Driven by Label Expansions of Existing Therapies and Less Impacted by Novel Agents 2.5 What Do Physicians Think?

3 Introduction

4 Disease Overview 4.1 Etiology and Pathophysiology 4.2 Diagnosis and Symptoms

5 Epidemiology 5.1 Disease Background 5.2 Risk Factors and Comorbidities 5.3 Global and Historical Trends 5.4 Forecast Methodology 5.4.1 Sources 5.4.2 Sources Not Used 5.5 Forecast Assumptions and Methods 5.5.1 8MM 5.6 Epidemiological Forecast for HL (2019-2029) 5.6.1 Diagnosed Incident Cases of HL 5.6.2 Diagnosed Incident Cases of Classical HL 5.6.3 Age-Specific Diagnosed Incident Cases of Classical HL 5.6.4 Sex-Specific Diagnosed Incident Cases of Classical HL 5.6.5 Diagnosed Incident Cases of Classical HL by Cancer Stage 5.6.6 Diagnosed Incident Cases of Classical HL by Cancer Subtypes 5.6.7 Five-Year Diagnosed Prevalent Cases of Classical HL 5.6.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant HL 5.7 Discussion 5.7.1 Epidemiological Forecast Insight 5.7.2 Limitations of the Analysis 5.7.3 Strengths of the Analysis

6 Current Treatment Options 6.1 Treatment Overview

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7tkcvl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Formats available:

The rest is here:
Hodgkin's Lymphoma in 8 Major Markets, 2019-2029 - Anticipated Label Expansions of Currently Marketed Therapies is a Key Driver - GlobeNewswire

Potential Impact of COVID-19 on Research report explores the Autoimmune Disorders Treatment Market for the forecast period, 2020-2026 – 3rd Watch News

Autoimmune Disorders Treatment Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Sanofi, Merck, Pfizer) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Autoimmune Disorders Treatment industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Autoimmune Disorders Treatment Market describe Autoimmune Disorders Treatment Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.

Key Target Audience of Autoimmune Disorders Treatment Market:Manufacturers of Autoimmune Disorders Treatment, Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Autoimmune Disorders Treatment market.

Get Free Sample PDF (including full TOC, Tables and Figures)of Autoimmune Disorders Treatment[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2374588

In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Autoimmune Disorders Treatment Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Summary of Autoimmune Disorders Treatment Market:Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in women than in men, which results from the influence of estrogen on immune system.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autoimmune Disorders Treatment market foreach application, including-

Systemic autoimmune diseases Localized autoimmune diseases

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Bridge therapy Recombinant technology Fecal bacteriotherapy Hematopoietic stem-cell transplantation Phototherapy Helminthic therapy Activation-induced assays Cytometry by time-of-flight mass spectrometry

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2374588

Important Autoimmune Disorders Treatment Market Data Available In This Report:

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Go here to read the rest:
Potential Impact of COVID-19 on Research report explores the Autoimmune Disorders Treatment Market for the forecast period, 2020-2026 - 3rd Watch News

Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2020 To 2026 – Cole of Duty

Global Stem Cell Therapy Market Size, Status And Forecast 2020-2026

Global Stem Cell Therapy Market Size research report with COVID-19 impact is considered to be an extremely intelligent and deep assessment of the present industrial conditions along with the overall Stem Cell Therapy market size estimated from 2020 to 2026. The study report also showcases a comprehensive analysis of the leading business programs, Stem Cell Therapy future market share, and business-oriented planning, etc. The report investigates desirable factors related to the current industrial situations, Stem Cell Therapy market growth rates, demands, differentiable business-oriented strategies used by the Stem Cell Therapy market manufacturers/Key players concerning distinct tactics and the futuristic prospects in brief.

(Special Offer: Available up to 30% Discount for a limited time only):

Get a Free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread/inquiry?source=colodduty&Mode=54

The research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Top Companies in the Global Stem Cell Therapy Market: MEDIPOST,Holostem Terapie Avanzate,Anterogen,NuVasive,Osiris Therapeutics,BIOTIME,RTI Surgical,AlloSource,JCR Pharmaceuticals,BrainStorm Cell Therapeutics,Pharmicell,Advanced Cell Technology,Caladrius.and others.

This report segments the global Stem Cell Therapy market on the basis of Types are:

On the basis of Application, the Global Stem Cell Therapy market is segmented into:

For comprehensive understanding of market dynamics, the global Stem Cell Therapy market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Avail Discount at

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread/discount?source=colodduty&mode=54

-Comprehensive assessment of all opportunities and risk in the Stem Cell Therapy market.

-Stem Cell Therapy market recent innovations and major events.

-Detailed study of business strategies for growth of the Stem Cell Therapy market-leading players.

-Conclusive study about the growth plot of Stem Cell Therapy market for forthcoming years.

-In-depth understanding of Stem Cell Therapy market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Stem Cell Therapy market.

Browse the report description and TOC:

https://www.marketinsightsreports.com/reports/05052012760/global-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?source=colodduty&Mode=54

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

IrfanTamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More here:
Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2020 To 2026 - Cole of Duty

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Cole of Duty

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The company profile section also focusses on companies planning expansions along with mergers & acquisitions, new initiatives, R&D updates and financial updates. But, one of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Therapy report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. The companies focused on in this report are pioneers in the Stem Cell Therapy market. Right from history to future plans the report give a detailed roadmap of the industry that the readers can rely on. The uplifting of any region in the global market is dependent upon the market players working in that region.

In the final section of the report on Stem Cell Therapy Market, the dashboard view of the companies is provided, to compare the current industrial scenario and their contribution in total Stem Cell Therapy Market. Moreover, it is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on the in-depth assessment of their capabilities and success in the Stem Cell Therapy Marketplace.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original post:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Cole of Duty

Cancer Stem Cell Therapy Industry 2020: Global Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report…

TheGlobal Cancer Stem Cell Therapy Marketwas estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026.

The market is primarily driven by increasing number of cancer patients suffering from many different types of cancer. In addition, stem cell therapy is a painless and incision less treatment procedure is likely to boost the market growth.

However, lack of suitable and donor matching sample might restrict the market growth.

Get Sample Copy of this Report @www.orianresearch.com/requestle/1040620

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Top Key Companies Analyzed inGlobal Cancer Stem Cell Therapy Market are Thermo Fisher Scientific, Merck Kgaa, Bionomics, Lonza, Stemline Therapeutics, Miltenyi Biotec, Promocell, Macrogenics, Oncomed Pharmaceuticals and Irvine Scientific

Key Benefit of This Report:

Global Cancer Stem Cell Therapy Industry 2019 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share a question if any before the purchase on this report @www.orianresearch.com/040620

Target Audience:

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration.

Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

Get Direct Copy of this Report @www.orianresearch.com/checkout/1040620

Major Points Covered in Table of Contents:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Cancer Stem Cell Therapy Market Overview

5 Global Cancer Stem Cell Therapy Market, by Product Type

6 Global Cancer Stem Cell Therapy Market, by Application

7 Global Cancer Stem Cell Therapy Market by Region

8 Competitive Landscape

9 Company Profiles

10 Key Insights

Customization Service of the Report: Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us: Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us: Ruwin Mendez Vice President Global Sales & Partner Relations Orian Research Consultants US: +1 (832) 380-8827 | UK: +44 0161-818-8027 Email:[emailprotected] Website: http://www.orianresearch.com/

Here is the original post:
Cancer Stem Cell Therapy Industry 2020: Global Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report...

Recovering from Cancer, a Stem Cell Transplant and Coronavirus – Cancer Health Treatment News

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

The rest is here:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Ionis, leading MS researcher throw antisense at a new type of brain cells – Endpoints News

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

Read more from the original source:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News